enzh-TWfrdeitjaptrues

The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia Web site is intended to provide general information about the program, its care and research programs, and about Waldenstrom's Macroglobulinemia and related diseases. This site also provides links to health information that may be written by Dana-Farber staff or by outside providers, and access (links) to some external Web sites for your convenience. The Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible for the availability, accuracy, or content of these external sites, nor does it endorse them.

No Medical Advice Given
This site is not an attempt to practice medicine or provide specific medical advice, nor does the use of the site establish a doctor-patient relationship. For medical treatment or answers to personal questions, we strongly encourage you to consult with a qualified health care provider. For advice about your own care, please ask your doctor!

Restrictions on Use
You assume full responsibility for using the information on this site, and you understand and agree that the Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose. The Dana-Farber Waldenstrom's Macroglobulinemia Program also does not warrant that access to the site will be error- or virus-free.

Copyright Infringement
Material on the Dana-Farber Waldenstrom's Macroglobulinemia Program Web site is protected by copyright law. Unless otherwise stated, users may print or download information from this site for personal, non-commercial use only. Permission to reprint or otherwise reproduce any document in whole or in part is prohibited, unless prior written consent is obtained from the copyright owner.

Latest Bing Center News

Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update

Advances in Multiple Myeloma and Waldenstrom’s Macroglobulinemia including COVID-19 Update

Please join the Center for Multiple Myeloma for a free webinar for patients and families to learn about the most recent updates in muliple myeloma and Waldenstrom's macroglobulinemia including the impact of COVID-19 and vaccination.

Read more..

The first issue of the 22nd volume of the IWMF Torch is now online!

The first issue of the 22nd volume of the IWMF Torch is now online!

Greetings to the entire WM community worldwide! Happy to have 2020 behind us, we now focus on COVID vaccines being widely available early in 2021. We all look forward eventually to being able to visit with our loved ones and share good times again.

Read more..

Waldenstrom Macroglobulinemia Patient Story: 17-Year Survivor

Waldenstrom Macroglobulinemia Patient Story: 17-Year Survivor

When Peter DeNardis was diagnosed with Waldenstrom macroglobulinemia 17 years ago, he had no idea what his next steps would be. Follow along to hear the story of his diagnosis, treatment journey and where he is now, including all of the “peaks and valleys” that come along with navigating cancer. He also shares personal advice for those who are newly diagnosed with Waldenstrom macroglobulinemia.

Read more..

New Treatment Options for Waldenstrom Macroglobulinemia - ASH 2020 Report

New Treatment Options for Waldenstrom Macroglobulinemia - ASH 2020 Report

Can New Drug Combinations Bring More Effective Treatment Options? New combination drug regimens are being studied for the treatment of Waldenstrom macroglobulinemia (WM). In this segment, Dr. Jorge Castillo, MD, of Dana-Farber Cancer Institute updates patients on the information presented at the recent American Society of Hematology (ASH) conference and suggests that Waldenstrom patients pay attention to the combination of ibrutinib and rituximab (INNOVATE Study), that have shown faster and deeper responses over time versus rituximab alone.

Read more..

#finishSTRONG Challenge - Dr. Edward Laane, Running for Waldenstroms!

#finishSTRONG Challenge - Dr. Edward Laane, Running for Waldenstroms!

Dr. Edward Laane has completed his 3 events in the 2020 B.A.A. Virtual #finishSTRONG Challenge! His official times for the 5K, 10K, and Half Marathon are listed below.

Read more..

North America SGL Check-in Call with Drs Jorge Castillo & Shayna Sarosiek (Recorded Zoom Call)

North America SGL Check-in Call with Drs Jorge Castillo & Shayna Sarosiek (Recorded Zoom Call)

Operational roles & functions of the Bing Center, as well as general WM questions regarding the current Pfizer, Moderna and AstraZeneca COVID-19 Vaccines. Also an update from the latest ASH conference. Recorded December 9, 2020.

Read more..

Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s Macroglobulinemia

Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s Macroglobulinemia

Christian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.

Read more..

Bing Neel Support Group Meeting - 11/22/2020 - Video

Bing Neel Support Group Meeting - 11/22/2020 - Video

Thank you so much for your interest in our recent Bing-Neel Syndrome support group meeting. Many of you were able to join the Zoom meeting live, while others volunteered to watch the recorded Zoom video [https://youtu.be/XQoqKzMshSI]. Many thanks to all who helped make this possible (the doctors, the IWMF office, The Bing Center for WM, the local support group members who helped plan, and all of you for your patience with me in pulling this together).

Read more..

Addressing Unmet Needs in WM (Webcast)

Addressing Unmet Needs in WM (Webcast)

With a focus on the latest clinical trial data supporting individualized treatment strategies, this accredited, on-demand activity discusses best practices for addressing unmet needs in treatment selection, sequencing, and disease monitoring in Waldenström macroglobulinemia (WM).

Read more..

Great Debates in Hematological Malignancies - 2021

Great Debates in Hematological Malignancies - 2021

We're pleased to announce that registration is now open for the 2021 Great Debates & Updates Conferences. Each meeting will cover the most critical updates occurring in the field, while incorporating a distinct focus on the latest advances and treatment options.

Read more..